Myo-inositol Plus Alpha-lactalbumin in PCOS Myo-inositol-resistant Patients
NCT ID: NCT03667443
Last Updated: 2025-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2022-06-13
2022-12-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Improved Effects of MI Plus Alpha-LA in PCOS
NCT03422289
Myo-inositol, Alpha-Lactalbumin and Folic Acid Treatment in PCOS
NCT04645745
Myo-Inositol for Infertility in PCOS
NCT04407754
Interest of Myo-inositol Supplementation in Women With Polycystic Ovarian Syndrome
NCT03059173
Myo-inositol as Pretreatment in Hyperandrogenic PCOS Patients
NCT03767569
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Myo-inositol plus folic
Myo-inositol + folic a.
3 months of treatment
Myo-inositol + folic a. + α-lactalbumin
Myo-inositol + folic a. + α-lactalbumin
3 months of treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Myo-inositol + folic a. + α-lactalbumin
3 months of treatment
Myo-inositol + folic a.
3 months of treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Other conditions causing ovulatory disorders and/or androgens hyper production such as: hyperprolactinemia, hypothyroidism, adrenal hyperplasia and Cushing syndrome
* Hormonal and/or pharmacological treatments in the previous 3 months that could interfere with ovulation
* Drastic changes in diet
* Treatment with product containing Myo-inositol in the previous 3 months
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Lo.Li.Pharma s.r.l
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aleksandrovska University Hospital
Sofia, , Bulgaria
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MILA
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.